An Argentine federal judge dismissed the criminal case against President Javier Milei, his sister Karina, and others regarding the promotion of the LIBRA memecoin, which crashed after its 2025 launch. The judge ruled Milei's promotion did not constitute fraud due to lack of evidence of deception, despite LIBRA losing over 95% of its value and $99 million withdrawn by wallets linked to its creator. The case, seen as politically motivated ahead of Argentina's 2025 midterm elections, may still face appeals from investors removed as plaintiffs. Milei denied wrongdoing and said he acted in good faith, withdrawing support after learning more about LIBRA.
The Argentine judge's dismissal of the LIBRA memecoin case offers context for cryptocurrency market activity. For readers following crypto, here is Pluang's market snapshot as of Oct 24, 2026 21:01 WIB: Out of 50 major cryptocurrencies, only 5 rose while 43 fell. VeChain (VET) dropped 5.13% to Rp125 with 88% of orders selling, contrasting with Cardano (ADA) and SushiSwap (SUSHI), which fell less than VET but saw strong buying interest at 75% and 79% respectively, priced at Rp3,743 and Rp3,722.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
